Literature DB >> 25373075

Painful ophthalmoplegia: a case of Tolosa-Hunt syndrome.

Mohenish K Singh1, Brittany Marshall2, John Hawley2.   

Abstract

Unilateral painful opthalmoplegia involving the third, fourth, or sixth cranial nerve in association with a retro-orbital mass should be evaluated for rheumatologic conditions and malignancy. The assessment may require a biopsy of the mass. Once cancer and autoimmune conditions such as sarcoidosis have been ruled out, Tolosa-Hunt should be considered. Tolosa-Hunt is a rare condition that presents as an acute unilateral eye pain with motor dysfunction and responds to prolonged treatment with corticosteroids. Presented is a case of Tolosa-Hunt syndrome. Reprint &
Copyright © 2014 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Year:  2014        PMID: 25373075     DOI: 10.7205/MILMED-D-14-00265

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  5 in total

1.  Tolosa-Hunt syndrome: an arcane pathology of cavernous venous sinus.

Authors:  Adeel Arshad; Shahzaib Nabi; Muhammad Siyab Panhwar; Ali Rahil
Journal:  BMJ Case Rep       Date:  2015-08-20

Review 2.  Tolosa-Hunt Syndrome: A Review of Diagnostic Criteria and Unresolved Issues.

Authors:  Paromita Dutta; Kamlesh Anand
Journal:  J Curr Ophthalmol       Date:  2021-07-05

3.  Immune Reconstitution Inflammatory Syndrome and Shingles Associated with a Combined Paralysis of Three Oculomotor Nerves: A Case Report.

Authors:  P W Atipo-Tsiba; E S Kombo Bayonne
Journal:  Ethiop J Health Sci       Date:  2016-05

4.  A 17-Year-Old Girl With Unilateral Headache and Double Vision.

Authors:  Larissa G Rodriguez-Homs; Mark Goerlitz-Jessen; Samrat U Das
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

5.  Acupuncture for ophthalmoplegia: Protocol for a systematic review.

Authors:  Meiqi Ji; Yali Qin; Yingxin Zi; Rui Wang; Huan Meng; Zongchun Yang; Qi Zhao; Ming Jin
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.